RxDoctor Payments Data

Mohammed Alawad, MD

Internal Medicine · Chicago Ridge, ILNPI 1952357436

Payments from drug & device makers

$1,108in general payments, 2019–2025

Across 48 payments — averaging $23.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$277
  • Pfizer$168
  • AstraZeneca$123
  • GSK$105
  • Astellas Pharma US Inc$100
  • Sanofi-aventis U.S. LLC$88
  • plus $247 from 10 others

What the payments were for

  • Food & beverage$1,00891%
  • Education$1009%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,108 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$206,720
Medicare patients
358
Services billed
3,176

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide117$127,252
EliquisApixaban155$126,907
JardianceEmpagliflozin91$73,704
Xeljanz XrTofacitinib Citrate11$64,052
Trelegy ElliptaFluticasone/Umeclidin/Vilanter85$63,427
JanuviaSitagliptin Phosphate36$41,337
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog71$29,905
TrulicityDulaglutide15$29,634
TradjentaLinagliptin35$28,562
FarxigaDapagliflozin Propanediol24$23,149
MyrbetriqMirabegron27$21,864
LinzessLinaclotide39$20,284
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog20$19,211
Lantus SolostarInsulin Glargine,hum.Rec.Anlog87$13,103
VascepaIcosapent Ethyl33$12,257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$14$127,252117 claims
PfizerEliquis$168$126,907155 claims
Boehringer IngelheimJardiance, Tradjenta$20$102,266126 claims
GSKTrelegy Ellipta, Arexvy, Shingrix$105$78,426146 claims
MerckJanuvia$11$41,33736 claims
AstraZenecaFarxiga, Crestor$123$26,11336 claims
Astellas Pharma US IncMyrbetriq$100$21,86427 claims
AbbVieLinzess$42$20,28439 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago Ridge

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →